Emerging Targeted and Immune-Based Therapies in Sarcoma.

  title={Emerging Targeted and Immune-Based Therapies in Sarcoma.},
  author={Seth M Pollack and Matthew Ingham and Matthew B. Spraker and Gary K Schwartz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={36 2},
  • S. PollackM. Ingham G. Schwartz
  • Published 10 January 2018
  • Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Soft tissue and bone sarcomas are malignancies of mesenchymal origin, and more than 50 subtypes are defined. For most sarcomas, locally advanced or unresectable disease is still treated with cytotoxic chemotherapy. Recently, our understanding of subtype-specific cancer biology has expanded, and it has revealed distinct molecular alterations responsible for tumor initiation and progression. These findings have motivated the development of targeted therapies that are being evaluated in subtype… 

Figures and Tables from this paper

Role of Virus-Directed Therapy in Soft Tissue Sarcoma

Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy or targeted therapies may yield increased potency, improve antitumor efficacy of oncolytic virotherapy, and offer a new prospect for the treatment of sarcoma.

Genomic-guided precision therapy for soft tissue sarcoma

This review will focus on the progress of genomic-guided therapy tailored to each molecular alteration of different STS histologies, with the advancement and accessibility of molecular diagnosis and next-generation sequencing.

Role of immunotherapy in Ewing sarcoma

An overview of ES biology, features of ES tumor microenvironment (TME), and various tumor-associated antigens that can be targeted with immune-based approaches including cancer vaccines, monoclonal antibodies, T cell receptor-transduced T cells, and chimeric antigen receptor T cells are provided.

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma

The authors explain the rationale for immune checkpoint inhibition and radiation therapy and highlight new studies testing this combination in the neoadjuvant setting for patients with high‐risk STS.

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review

Trans translocation-related sarcomas are heterogeneous, and although synovial sarcoma a poorly infiltrated and have a poor response rate to ICI, ASPS largely benefit from ICB monotherapy or its association with antiangiogenics agents.

Cancer Stem Cells in Soft-Tissue Sarcomas

The published evidence of CSCs in STS is reviewed, discussing the molecular characteristic of C SCs, the commonly used isolation techniques and the new possibilities of targeting CSC's as a way to improve STS treatment and consequently patient outcome.

Immunotherapeutic strategies for sarcoma: current perspectives.

The immune microenvironment and how it relates to immunoresponsiveness is discussed, focusing on the advances in immunotherapy (immune checkpoint inhibitors, vaccines and adoptive cell therapies), the use of which will hopefully lead to improved outcomes for patients with sarcomas.

Sarcoma treatment in the era of molecular medicine

This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology, meant for a broad readership ranging from novices to experts in the field of Sarcoma.

Immunotherapy of sarcomas with modified T cells

Therapeutic tools to improve the specificity, signaling, proliferation and persistence of modified TCRs and augment clinical responses through safe manipulation of the sarcoma TME will be necessary to harness the full potential of this approach.

Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy

This review will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities and examine the role of EGFR, mTOR, and polykinase inhibitors in the management of local and disseminated disease.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

A patient with a metastatic soft-tissue sarcoma with an LMNA-NTRK1 fusion had rapid and substantial tumor regression with a novel, highly selective TRK inhibitor, LOXO-101, providing the first clinical evidence of benefit from inhibiting TRK fusions.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

    N. AhmedV. Brawley S. Gottschalk
    Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine Her2- CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

In conclusion, trabectedin has dual effects in liposarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the production of key inflammatory mediators.

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

This is the first report describing MGCD516 as a potent multi-kinase inhibitor in different models of sarcoma, superior to imatinib and crizotinib, both in vitro and in vivo.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patientswith leiomyosarcoma, synovial sarcomas, and other STS types.

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

The results indicate that selinexor has potent in vitro and in vivo activity against a wide variety of sarcoma models by inducing G1-arrest independent of known molecular mechanisms in GIST and LPS.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

    P. RobbinsR. Morgan S. Rosenberg
    Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
These observations indicate that TCR-based gene therapies directed against NY-ESO-1 represent a new and effective therapeutic approach for patients with melanoma and synovial cell sarcoma.